Cancer

Items 101-110 of 261

per page
Set Descending Direction
  1. DLL4 (human):Fc (human) (rec.)
    AG-40A-0077Y
    AG-40A-0077Y-C01010 µg
    CHF 290.00
    AG-40A-0077Y-C05050 µg
    CHF 530.00
    Replaces AG-40A-0077
    DLL4 (human):Fc (human) (rec.)
  2. DLL4 (human):Fc (human) (rec.) (highly active mutant)
    AG-40B-0176
    AG-40B-0176-C01010 µg
    CHF 350.00
    AG-40B-0176-C100100 µg
    CHF 1'080.00
    DLL4 (human):Fc (human) (rec.) (highly active mutant) (AG-40B-0176) binds to mNotch1 with higher affinity than WT DLL4:Fc. Method: Notch1 (mouse):Fc was coated on an ELISA plate at 1μg/ml. After blocking and washing steps, indicated concentrations
  3. DNER (extracellular domain) (human) (rec.)
    AG-40A-0137Y
    AG-40A-0137Y-C01010 µg
    CHF 265.00
    AG-40A-0137Y-30103 x 10 µg
    CHF 530.00
  4. DNER (extracellular domain) (human):Fc (human) (rec.)
    AG-40A-0119T
    AG-40A-0119T-C01010 µg
    CHF 170.00
    AG-40A-0119T-C05050 µg
    CHF 470.00
  5. DR6 (human):Fc (human) (rec)
    AG-40B-0011
    AG-40B-0011-C05050 µg
    CHF 170.00
    AG-40B-0011-30503 x 50 µg
    CHF 335.00
  6. EGF (human) (rec.) (His)
    CHI-HF-201EGF
    CHI-HF-201EGF-C01010 µg
    CHF 210.00
  7. EGF (human):Fc (human) (rec.)
    CHI-HF-210EGF
    CHI-HF-210EGF-C100100 µg
    CHF 240.00
  8. EGFR, Soluble (human) (rec.)
    AG-40T-0041
    AG-40T-0041-C02525 µg
    CHF 620.00
  9. Fas (human):Fc (human) (rec.)
    AG-40B-0082
    AG-40B-0082-C05050 µg
    CHF 300.00
    AG-40B-0082-30503 x 50 µg
    CHF 600.00
  10. FasL (human) (multimeric) (rec.)
    AG-40B-0130
    AG-40B-0130-C01010 µg
    CHF 380.00
    AG-40B-0130-30103 x 10 µg
    CHF 760.00
    Oligomerisation of FasL (h) efficiently triggers Jurkat cell death.Method: Jurkat cells were treated O/N with the indicated concentrations of FasL (human) (multimeric) (rec.) (Prod. No. AG-40B-0130), Fc:FasL, Soluble (human) (rec.) (Prod. No.

Items 101-110 of 261

per page
Set Descending Direction
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.